Takeda (TSE:4502/NYSE:TAK) announced the completion of the 7-year pivotal Phase 3 Tetravalent Immunization against Dengue Efficacy Study (TIDES) trial evaluating its dengue vaccine, QDENGA®?(Dengue ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback